Our Phone Systems are Down
Please contact us the following ways:
- Use PATIENT PORTAL to send a message to your provider
- Click on SCHEDULE APPOINTMENT if you need to be seen.
Clinical research
Participation in clinical trials research enables Central Ohio Urology Group physicians to provide their patients with direct access to cutting-edge advances in medical technology and pharmaceutical development.
Our research trials are conducted with the highest level of honesty and integrity.
Contributions to a patient’s health and well-being are important — and patient safety and privacy are our priorities.
Before a new medical treatment can be marketed, manufacturers must show, through adequate and well-controlled clinical studies, that it is safe and effective. Participation in clinical research trials enables our physicians to gain insight and experience in many areas of leading-edge technology and pharmaceutical development. Our contribution to significant advances in urologic and genitourinary research aligns with our mission to bring the newest and most advanced treatments and procedures to our patients. For more information on our clinical trials, please call (614) 396-2684 or Sarah.Faisal@us-uro.com.
Meet the research team
Ben Carey
Research Supervisor
Madilyn Hoff
Study Coordinator
Clinical trials at Central Ohio Urology Group
Bladder cancer
Sunrise-3:
(closed for enrollment)
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)
Able-41:
(open for enrollment)
Adstiladrin: Early Utilization and Outcomes in the Real World Setting in the United States
Sunrise-5:
(open for enrollment)
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Prostate cancer
ProvONE:
(open for enrollment)
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Merck-004:
(open for enrollment)
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA
Libertas:
(closed for enrollment)
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
Replace-CV:
(closed for enrollment)
Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)
ExoDx:
(open for enrollment)
Prostate Evaluation in Active Surveillance Patient Population
Optyx:
(open for enrollment)
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX (OPTYX)
Bladder pain
Ironwood C330-201:
(open for enrollment)
Phase 2 Study of IW 3300 for the Treatment of Bladder Pain in Subjects with Interstitial Cystitis/Bladder Pain Syndrome